Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets

22 Nov 2011

Abstract excerpt

The topoisomerase I (Top 1) poison irinotecan is an important component of the modern treatment of colorectal cancer. By stabilising Top 1-DNA complexes, irinotecan generates Top 1-linked DNA single-strand breaks that can evolve into double-strand breaks and ultimately cause cell death. However, cancer cells may overcome cell killing by releasing the stalled topoisomerase from DNA termini, thereby reducing the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to Lung Cancer Research Studies
Share to Neutropenia and Cancer Infections

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22108516
DOI: 10.1038/bjc.2011.498

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targetsPMID 22108516Read ↗

Clinical and Cellular Roles for TDP1 and TOP1 in Modulating Colorectal Cancer Response to IrinotecanSemantic proximity Read ↗

Resistance to TOP-1 Inhibitors: Good Old Drugs Still Can Surprise UsSemantic proximity Read ↗

DNA Repair and Resistance to Topoisomerase I Inhibitors: Mechanisms, Biomarkers and Therapeutic TargetsSemantic proximity Read ↗

Inhibition of Topoisomerase (DNA) I (TOP1): DNA Damage Repair and Anticancer TherapySemantic proximity Read ↗

Epigenetic changes in histone acetylation underpin resistance to the topoisomerase I inhibitor irinotecanSemantic proximity Read ↗

Recent Developments in Combination Chemotherapy for Colorectal and Breast Cancers with Topoisomerase InhibitorsSemantic proximity Read ↗

Targeting Topoisomerase I in the Era of Precision MedicineSemantic proximity Read ↗

Advances in DNA damage response inhibitors in colorectal cancer therapySemantic proximity Read ↗

In Vivo Topoisomerase I Inhibition Attenuates the Expression of Hypoxia-Inducible Factor 1α Target Genes and Decreases Tumor AngiogenesisSemantic proximity Read ↗

Targeting neddylation sensitizes colorectal cancer to topoisomerase I inhibitors by inactivating the DCAF13-CRL4 ubiquitin ligase complexSemantic proximity Read ↗

Topoisomerases and cancer chemotherapy: recent advances and unanswered questionsSemantic proximity Read ↗

Nonclassic Functions of Human Topoisomerase I: Genome-Wide and Pharmacologic AnalysesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.